Selective release of a cyclopamine glucuronide prodrug toward stem-like cancer cell inhibition in glioblastoma

Molecular Cancer Therapeutics

Volumn 13, Issue 9, 2014, Pages 2159-2169

  Balbous, Anaïs ^a,b,c   Renoux, Brigitte ^b   Cortes, Ulrich ^a,b,c   Milin, Serge ^c   Guilloteau, Karline ^a,b,c   Legigan, Thibaut ^b   Rivet, Pierre ^c   Boissonnade, Odile ^c   Martin, Sébastien ^c   Tripiana, Caroline ^c   Wager, Michel ^c   Bensadoun, René Jean ^c   Papot, Sébastien ^b   Karayan Tapon, Lucie ^a,b,c  

^a Centre National de la Recherche Scientifique   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPAMINE; GLUCURONIDE; METHYLCELLULOSE; PRODRUG; SONIC HEDGEHOG PROTEIN; VERATRUM ALKALOID;

ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CANCER STEM CELL; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG DESIGN; DRUG SCREENING; FEMALE; GLIOBLASTOMA; HUMAN; IC50; MOUSE; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GLIOBLASTOMA; GLUCURONIDES; HEDGEHOG PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; METHYLCELLULOSE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PRODRUGS; VERATRUM ALKALOIDS;

EID: 84907217863     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-1038     Document Type: Article

References (48)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352: 987-96.
2. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64: 7011-21.
3. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004;432: 396-401.
4. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010;17: 362-75.
5. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells showdifferential growth characteristics and molecular profiles. Cancer Res 2007;67: 4010-5.
6. Son MJ, Woolard K, Nam D-H, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009;4: 440-52.
7. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+cancer stem cells in glioblastoma. Mol Cancer 2006;5: 67.
8. Kang J, Shakya A, Tantin D. Stem cells, stress, metabolism and cancer: a drama in two Octs. Trends Biochem Sci 2009;34: 491-9.
9. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444: 756-60.
10. Dahmane N, Lee J, Robins P, Heller P, Ruizi Altaba A. Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature 1997;389: 876-81.
11. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003;422: 313-7.
12. Sanchez P, Hernández AM, Stecca B, Kahler AJ, De Gueme AM, Barrett A, et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci U S A 2004;101: 12561-6.
13. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003;425: 846-51.
14. Kubo M, Nakamura M, Tasaki A, Yamanaka N, Nakashima H, Nomura M, et al. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 2004;64: 6071-4.
15. Goodrich LV, Milenković L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997;277: 1109-13.
16. Sandberg CJ, Altschuler G, Jeong J, Strømme KK, Stangeland B, Murrell W, et al. Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt-signaling and a fingerprint associated with clinical outcome. Exp Cell Res 2013;319: 2230-43.
17. Dahmane N, Sánchez P, Gitton Y, Palma V, Sun T, Beyna M, et al. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Dev Camb Engl 2001;128: 5201-12.
18. Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007;25: 2524-33.
19. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruizi Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal and tumorigenicity. Curr Biol CB 2007;17: 165-72.
20. Cooper MK, Porter JA, Young KE, Beachy PA. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 1998;280: 1603-7.
21. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 2002;16: 2743-8.
22. Chen JK, Taipale J, Young KE, Maiti T, Beachy PA. Small molecule modulation of Smoothened activity. Proc Natl Acad Sci U S A 2002;99: 14071-6.
23. Kolterud A, Toftgard R. Strategies for Hedgehog inhibition and its potential role in cancer treatment. Drug Discov Today Ther Strateg 2007;229-35.
24. Hamon F, Renoux B, Chadéneau C, Muller J-M, Papot S. Study of a cyclopamine glucuronide prodrug for the selective chemotherapy of glioblastoma. Eur J Med Chem 2010;45: 1678-82.
25. Renoux B, Legigan T, Bensalma S, Chadéneau C, Muller J-M, Papot S. A new cyclopamine glucuronide prodrug with improved kinetics of drug release. Org Biomol Chem 2011;9: 8459-64.
26. Tranoy-Opalinski I, Legigan T, Barat R, Clarhaut J, Thomas M, Renoux B, et al. β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update. Eur J Med Chem 2014;74: 302-13.
27. Nygren C, von Holst H, Månsson JE, Fredman P. Increased activity of lysosomal glycohydrolases in glioma tissue and surrounding areas from human brain. Acta Neurochir 1997;139: 146-50.
28. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998;58: 1195-201.
29. Juan T-Y, Roffler SR, Hou H-S, Huang S-M, Chen K-C, Leu Y-L, et al. Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity. Clin Cancer Res 2009;15: 4600-11.
30. Wolburg H, Noell S, Fallier-Becker P, Mack AF, Wolburg-Buchholz K. The disturbed blood-brain barrier in human glioblastoma. Mol Aspects Med 2012;33: 579-89.
31. Weiss N, Miller F, Cazaubon S, Couraud P-O. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 2009;1788: 842-57.
32. Wolburg H, Wolburg-Buchholz K, Kraus J, Rascher-Eggstein G, Liebner S, Hamm S, et al. Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol 2003;105: 586-92.
33. Liu H-L, Hua M-Y, Chen P-Y, Chu P-C, Pan C-H, Yang H-W, et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 2010;255: 415-25.
34. Villalva C, Martin-Lannerée S, Cortes U, Dkhissi F, Wager M, Le Corf A, et al. STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy? Int J Cancer 2011;128: 826-38.
35. Villalva C, Cortes U, Wager M, Tourani J-M, Rivet P, Marquant C, et al. O6-Methylguanine-Methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions. Int J Mol Sci 2012;13: 6983-94.
36. Balbous A, Cortes U, Guilloteau K, Villalva C, Flamant S, Gaillard A, et al. A mesenchymal glioma stem cell profile is related to clinical outcome. Oncogenesis 2014;3: e91.
37. Van den Brink GR, Hardwick JC, Tytgat GN, Brink MA, Ten Kate FJ, Van Deventer SJ, et al. Sonic hedgehog regulates gastric gland morphogenesis in man and mouse. Gastroenterology 2001;121: 317-28.
38. Van den Brink GR, Bleuming SA, Hardwick JCH, Schepman BL, Offerhaus GJ, Keller JJ, et al. Indian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation. Nat Genet 2004;36: 277-82.
39. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011;8: 97-106.
40. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002;297: 1559-61.
41. Sanchez P, Ruizi Altaba A. In vivo inhibition of endogenous brain tumors through systemic interference of Hedgehog signaling in mice. Mech Dev 2005;122: 223-30.
42. Feldmann G, Habbe N, Dhara S, Bisht S, Alvarez H, Fendrich V, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008;57: 1420-30.
43. Lipinski RJ, Hutson PR, Hannam PW, Nydza RJ, Washington IM, Moore RW, et al. Dose- and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the hedgehog signaling antagonist cyclopamine in the mouse. Toxicol Sci Off J Soc Toxicol 2008;104: 189-97.
44. Ruizi Altaba A, Mas C, Stecca B. The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol 2007;17: 438-47.
45. Beier D, Röhrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008;68: 5706-15.
46. Legigan T, Clarhaut J, Renoux B, Tranoy-Opalinski I, Monvoisin A, Berjeaud J-M, et al. Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin. J Med Chem 2012;55: 4516-20.
47. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366: 2171-9.
48. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC- 0449. N Engl J Med 2009;361: 1173-8.